Agilent Technologies will sell Resolution Bioscience to Exact Sciences, a leading provider of cancer screening and diagnostic tests. Financial terms of the agreement were not disclosed. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.

Agilent Technologies will sell Resolution Bioscience to Exact Sciences, a leading provider of cancer screening and diagnostic tests. Financial terms of the agreement were not disclosed. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.

“We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, senior vice president, Agilent, and president, Diagnostics and Genomics Group. “Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction.”

Brian Baranick, general manager of Precision Oncology at Exact Sciences, commented: “We are excited to work with the Resolution Bioscience team to integrate their innovative diagnostics into our precision oncology portfolio. Resolution Bioscience’s high-quality liquid therapy selection platform perfectly complements our OncoExTra test, allowing Exact Sciences to help more cancer patients determine their best treatment options.”

Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX Breast Recurrence Score test is recognized as a standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumour profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes, the OncoExTra test is one of the most comprehensive molecular tests available to patients. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations.